Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model

The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatmen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of ophthalmology 1993-12, Vol.116 (6), p.700-707
Hauptverfasser: Helm, Craig J., Holland, Gary N., Lin, Robert, Berlin, O. George W., Bruckner, David A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 707
container_issue 6
container_start_page 700
container_title American journal of ophthalmology
container_volume 116
creator Helm, Craig J.
Holland, Gary N.
Lin, Robert
Berlin, O. George W.
Bruckner, David A.
description The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatments significantly reduced the number of organisms in treated eyes compared to untreated, control eyes (all P values < .001). No significant difference in treatment efficacy was found between the three treatment groups (all P values ≥ .48), although ciprofloxacin (3 mg/ml) was more effective than clarithromycin (20 mg/ml) after excluding outliers (P = .01). All treatments stabilized or reduced the size of stromal infiltrates after four days of therapy, whereas infiltrates continued to enlarge in untreated eyes. These results suggest that topical clarithromycin, topical ciprofloxacin, and combined amikacin and vancomycin may all be clinically useful for treating M. fortuitum keratitis. Both clarithromycin and ciprofloxacin were better tolerated than combined amikacin and vancomycin. This study supports the further development of clarithromycin, a new macrolide antibiotic, as a topical drug for treatment of M. fortuitum keratitis.
doi_str_mv 10.1016/S0002-9394(14)73469-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76082992</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002939414734695</els_id><sourcerecordid>76082992</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-358c6e55a1987ffcd46380d6e45349486417538e6c0d6ab506c977bed22877ba3</originalsourceid><addsrcrecordid>eNqFkEtLxTAQhYMoen38BKEr0UU1afNciVx8oeLC6zqk6VQibXNNUsF_b-4Dt64mmXPmTPIhdErwJcGEX71hjKtS1YqeE3ohaspVyXbQjEihSiIV2UWzP8sBOozxM1-5oGIf7cuKYSyqGbJzPyxNcNGPhe-KhV86a_riZkyucT45G4vOh2IRwCQ3fhQvP9Y3xiYIbhpWUppcyqcnCNmQXCzcWJgxB7gh57z4FvpjtNeZPsLJth6h97vbxfyhfH69f5zfPJe25jiVNZOWA2OGKCm6zraU1xK3HCirqaKSUyJYLYHb3DQNw9wqIRpoq0rmauojdLbJXQb_NUFMenDRQt-bEfwUteBYVkpV2cg2Rht8jAE6vQz5ueFHE6xXcPUarl6R04TqNVzN8tzpdsHUDND-TW1pZv16o0P-5beDoKN1MFpoXQCbdOvdPxt-AUmiiac</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76082992</pqid></control><display><type>article</type><title>Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Helm, Craig J. ; Holland, Gary N. ; Lin, Robert ; Berlin, O. George W. ; Bruckner, David A.</creator><creatorcontrib>Helm, Craig J. ; Holland, Gary N. ; Lin, Robert ; Berlin, O. George W. ; Bruckner, David A.</creatorcontrib><description>The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatments significantly reduced the number of organisms in treated eyes compared to untreated, control eyes (all P values &lt; .001). No significant difference in treatment efficacy was found between the three treatment groups (all P values ≥ .48), although ciprofloxacin (3 mg/ml) was more effective than clarithromycin (20 mg/ml) after excluding outliers (P = .01). All treatments stabilized or reduced the size of stromal infiltrates after four days of therapy, whereas infiltrates continued to enlarge in untreated eyes. These results suggest that topical clarithromycin, topical ciprofloxacin, and combined amikacin and vancomycin may all be clinically useful for treating M. fortuitum keratitis. Both clarithromycin and ciprofloxacin were better tolerated than combined amikacin and vancomycin. This study supports the further development of clarithromycin, a new macrolide antibiotic, as a topical drug for treatment of M. fortuitum keratitis.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/S0002-9394(14)73469-5</identifier><identifier>PMID: 8250072</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Topical ; Amikacin - therapeutic use ; Animals ; Ciprofloxacin - therapeutic use ; Clarithromycin - therapeutic use ; Colony Count, Microbial ; Corneal Stroma - microbiology ; Disease Models, Animal ; Drug Therapy, Combination - therapeutic use ; Eye Infections, Bacterial - drug therapy ; Keratitis - drug therapy ; Keratitis - microbiology ; Male ; Mycobacterium Infections, Nontuberculous - drug therapy ; Ophthalmic Solutions ; Rabbits ; Vancomycin - therapeutic use</subject><ispartof>American journal of ophthalmology, 1993-12, Vol.116 (6), p.700-707</ispartof><rights>1993 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-358c6e55a1987ffcd46380d6e45349486417538e6c0d6ab506c977bed22877ba3</citedby><cites>FETCH-LOGICAL-c360t-358c6e55a1987ffcd46380d6e45349486417538e6c0d6ab506c977bed22877ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9394(14)73469-5$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8250072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Helm, Craig J.</creatorcontrib><creatorcontrib>Holland, Gary N.</creatorcontrib><creatorcontrib>Lin, Robert</creatorcontrib><creatorcontrib>Berlin, O. George W.</creatorcontrib><creatorcontrib>Bruckner, David A.</creatorcontrib><title>Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatments significantly reduced the number of organisms in treated eyes compared to untreated, control eyes (all P values &lt; .001). No significant difference in treatment efficacy was found between the three treatment groups (all P values ≥ .48), although ciprofloxacin (3 mg/ml) was more effective than clarithromycin (20 mg/ml) after excluding outliers (P = .01). All treatments stabilized or reduced the size of stromal infiltrates after four days of therapy, whereas infiltrates continued to enlarge in untreated eyes. These results suggest that topical clarithromycin, topical ciprofloxacin, and combined amikacin and vancomycin may all be clinically useful for treating M. fortuitum keratitis. Both clarithromycin and ciprofloxacin were better tolerated than combined amikacin and vancomycin. This study supports the further development of clarithromycin, a new macrolide antibiotic, as a topical drug for treatment of M. fortuitum keratitis.</description><subject>Administration, Topical</subject><subject>Amikacin - therapeutic use</subject><subject>Animals</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Clarithromycin - therapeutic use</subject><subject>Colony Count, Microbial</subject><subject>Corneal Stroma - microbiology</subject><subject>Disease Models, Animal</subject><subject>Drug Therapy, Combination - therapeutic use</subject><subject>Eye Infections, Bacterial - drug therapy</subject><subject>Keratitis - drug therapy</subject><subject>Keratitis - microbiology</subject><subject>Male</subject><subject>Mycobacterium Infections, Nontuberculous - drug therapy</subject><subject>Ophthalmic Solutions</subject><subject>Rabbits</subject><subject>Vancomycin - therapeutic use</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLxTAQhYMoen38BKEr0UU1afNciVx8oeLC6zqk6VQibXNNUsF_b-4Dt64mmXPmTPIhdErwJcGEX71hjKtS1YqeE3ohaspVyXbQjEihSiIV2UWzP8sBOozxM1-5oGIf7cuKYSyqGbJzPyxNcNGPhe-KhV86a_riZkyucT45G4vOh2IRwCQ3fhQvP9Y3xiYIbhpWUppcyqcnCNmQXCzcWJgxB7gh57z4FvpjtNeZPsLJth6h97vbxfyhfH69f5zfPJe25jiVNZOWA2OGKCm6zraU1xK3HCirqaKSUyJYLYHb3DQNw9wqIRpoq0rmauojdLbJXQb_NUFMenDRQt-bEfwUteBYVkpV2cg2Rht8jAE6vQz5ueFHE6xXcPUarl6R04TqNVzN8tzpdsHUDND-TW1pZv16o0P-5beDoKN1MFpoXQCbdOvdPxt-AUmiiac</recordid><startdate>19931215</startdate><enddate>19931215</enddate><creator>Helm, Craig J.</creator><creator>Holland, Gary N.</creator><creator>Lin, Robert</creator><creator>Berlin, O. George W.</creator><creator>Bruckner, David A.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19931215</creationdate><title>Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model</title><author>Helm, Craig J. ; Holland, Gary N. ; Lin, Robert ; Berlin, O. George W. ; Bruckner, David A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-358c6e55a1987ffcd46380d6e45349486417538e6c0d6ab506c977bed22877ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Administration, Topical</topic><topic>Amikacin - therapeutic use</topic><topic>Animals</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Clarithromycin - therapeutic use</topic><topic>Colony Count, Microbial</topic><topic>Corneal Stroma - microbiology</topic><topic>Disease Models, Animal</topic><topic>Drug Therapy, Combination - therapeutic use</topic><topic>Eye Infections, Bacterial - drug therapy</topic><topic>Keratitis - drug therapy</topic><topic>Keratitis - microbiology</topic><topic>Male</topic><topic>Mycobacterium Infections, Nontuberculous - drug therapy</topic><topic>Ophthalmic Solutions</topic><topic>Rabbits</topic><topic>Vancomycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Helm, Craig J.</creatorcontrib><creatorcontrib>Holland, Gary N.</creatorcontrib><creatorcontrib>Lin, Robert</creatorcontrib><creatorcontrib>Berlin, O. George W.</creatorcontrib><creatorcontrib>Bruckner, David A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Helm, Craig J.</au><au>Holland, Gary N.</au><au>Lin, Robert</au><au>Berlin, O. George W.</au><au>Bruckner, David A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>1993-12-15</date><risdate>1993</risdate><volume>116</volume><issue>6</issue><spage>700</spage><epage>707</epage><pages>700-707</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><abstract>The efficacy of three topical antibiotic treatments for Mycobacterium fortuitum (strain ATCC-6841) keratitis were compared in rabbits. Rabbits were treated with ciprofloxacin (3 mg/ml) or clarithromycin (20 mg/ml) or a combination of amikacin (100 mg/ml) and vancomycin (50 mg/ml). All three treatments significantly reduced the number of organisms in treated eyes compared to untreated, control eyes (all P values &lt; .001). No significant difference in treatment efficacy was found between the three treatment groups (all P values ≥ .48), although ciprofloxacin (3 mg/ml) was more effective than clarithromycin (20 mg/ml) after excluding outliers (P = .01). All treatments stabilized or reduced the size of stromal infiltrates after four days of therapy, whereas infiltrates continued to enlarge in untreated eyes. These results suggest that topical clarithromycin, topical ciprofloxacin, and combined amikacin and vancomycin may all be clinically useful for treating M. fortuitum keratitis. Both clarithromycin and ciprofloxacin were better tolerated than combined amikacin and vancomycin. This study supports the further development of clarithromycin, a new macrolide antibiotic, as a topical drug for treatment of M. fortuitum keratitis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>8250072</pmid><doi>10.1016/S0002-9394(14)73469-5</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-9394
ispartof American journal of ophthalmology, 1993-12, Vol.116 (6), p.700-707
issn 0002-9394
1879-1891
language eng
recordid cdi_proquest_miscellaneous_76082992
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Administration, Topical
Amikacin - therapeutic use
Animals
Ciprofloxacin - therapeutic use
Clarithromycin - therapeutic use
Colony Count, Microbial
Corneal Stroma - microbiology
Disease Models, Animal
Drug Therapy, Combination - therapeutic use
Eye Infections, Bacterial - drug therapy
Keratitis - drug therapy
Keratitis - microbiology
Male
Mycobacterium Infections, Nontuberculous - drug therapy
Ophthalmic Solutions
Rabbits
Vancomycin - therapeutic use
title Comparison of Topical Antibiotics for Treating Mycobacterium fortuitum Keratitis in an Animal Model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T08%3A39%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Topical%20Antibiotics%20for%20Treating%20Mycobacterium%20fortuitum%20Keratitis%20in%20an%20Animal%20Model&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Helm,%20Craig%20J.&rft.date=1993-12-15&rft.volume=116&rft.issue=6&rft.spage=700&rft.epage=707&rft.pages=700-707&rft.issn=0002-9394&rft.eissn=1879-1891&rft_id=info:doi/10.1016/S0002-9394(14)73469-5&rft_dat=%3Cproquest_cross%3E76082992%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76082992&rft_id=info:pmid/8250072&rft_els_id=S0002939414734695&rfr_iscdi=true